Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 11:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1801–1824 of 3,500 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Protein Control Clear all

Conditions: Diabetes Mellitus
Interventions: Effect of Pulsatile IV insulin on diabetic pt blood markers, Effect of Pulsatile IV Insulin on blood markers; Procedure
Lead sponsor: Florida Atlantic University; Other
Eligibility: 21 Years to 85 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Plaque Psoriasis
Interventions: IDP-118 Lotion, IDP-118 Monad HP Lotion, IDP-118 Monad Taz Lotion, IDP-118 Vehicle Lotion; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 18
States / cities: Encino, California • San Diego, California • Santa Rosa, California + 15 more

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions: Paclitaxel, Carboplatin, Bevacizumab, IMNN-001; Drug
Lead sponsor: Imunon; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Baltimore, Maryland • New York, New York • Oklahoma City, Oklahoma + 1 more

Conditions: Staphylococcus Aureus, Community-acquired Infections, Staphylococcal Skin Infections
Interventions: 2% chlorhexidine gluconate (CHG) impregnated cloths, Comfort Bath cloths (placebo cloths); Drug
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years to 35 Years
Enrollment: 1,563 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Quantico, Virginia

Conditions: Hypertension, Mild Cognitive Impairment
Interventions: Candesartan, Lisinopril; Drug
Lead sponsor: Emory University; Other
Eligibility: 55 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Head and Neck Cancer
Interventions: cetuximab, cisplatin; Biological · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 73
States / cities: Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 54 more

Conditions: Hepatocellular Carcinoma
Interventions: Livmoniplimab, Budigalimab, Durvalumab, Atezolizumab, Bevacizumab, Tremelimumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 13
States / cities: Duarte, California • Irvine, California • Orange, California + 9 more

Conditions: COVID-19, SARS-CoV-2
Interventions: Abatacept, Placebo; Biological · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 7
States / cities: Hialeah, Florida • Louisville, Kentucky • Boston, Massachusetts + 2 more

Conditions: Non-segmental Vitiligo
Interventions: EI-001, Placebo; Biological · Other
Lead sponsor: Elixiron Immunotherapeutics (Hong Kong) Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Huntington Beach, California • Hollywood, Florida • Worcester, Massachusetts + 3 more

Conditions: Gastric Cancer, Cancer of the Stomach, Stomach Cancer, Gastroesophageal Junction
Interventions: Relatlimab + Nivolumab, Nivolumab, Paclitaxel, Ramucirumab; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 20
States / cities: Daphne, Alabama • Bakersfield, California • Fullerton, California + 17 more

Conditions: Healthy Lifestyle
Interventions: Red meat-based meal, No meat diet; Other
Lead sponsor: South Dakota State University; Other
Eligibility: 65 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Brookings, South Dakota

Conditions: HIV Infections
Interventions: rgp120/HIV-1 SF-2, MTP-PE/MF59; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 4
States / cities: St Louis, Missouri • Philadelphia, Pennsylvania • Nashville, Tennessee + 1 more

Conditions: Muscle Weakness
Interventions: Resistance exercise, Protein and HMB (see below) supplement; Other · Dietary Supplement
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 65 Years to 90 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: No. Little Rock, Arkansas

Conditions: Head Neck Cancer
Interventions: Medpulser Electroporation with Bleomycin, Surgical Excision; Combination Product · Procedure
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: San Diego, California

Conditions: Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma, Glioblastoma With Oligodendroglial Component, Recurrent Glioblastoma, Relapsed Glioblastoma
Interventions: Bevacizumab, Rindopepimut (CDX-110) with GM-CSF, KLH; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 45
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 37 more

Conditions: Cancer
Interventions: Not listed
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Insulin-like Growth Factor-1 Deficiency
Interventions: NutropinAq® (Somatropin [rDNA origin]), Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin]); Drug
Lead sponsor: Ipsen; Industry
Eligibility: 5 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Brisbane, California

Conditions: Turner Syndrome, Idiopathic Short Stature
Interventions: somatropin (rDNA); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 7 Years to 14 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Infertility
Interventions: AFOLIA, Gonal-f® RFF; Drug
Lead sponsor: Fertility Biotech AG; Industry
Eligibility: 35 Years to 42 Years · Female only
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 22
States / cities: Tempe, Arizona • Encino, California • Newark, Delaware + 18 more

Conditions: Alzheimer Disease
Interventions: Simvastatin, Placebo; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 35 Years to 69 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Early Stage Breast Cancer (Stage 0-III)
Interventions: Exercise Regimen; Other
Lead sponsor: Nevada Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Parkinson's Disease
Interventions: creatine, placebo; Drug · Other
Lead sponsor: University of Rochester; Other
Eligibility: Not listed
Enrollment: 1,741 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 48
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 40 more

Conditions: Sunburn
Interventions: oxytocin, placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Lupus Nephritis
Interventions: Iptacopan (part 1), Iptacopan (part 2), Placebo + standard of care, Iptacopan + placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 16
States / cities: Los Angeles, California • San Bernardino, California • Sylmar, California + 13 more

Search by objective public record fields.

Effect of Pulsatile IV Insulin on Circulating Risk Markers of Vascular and Metabolic Complications in Pts With Diabetes

Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Chlorhexidine Impregnated Cloths to Prevent Skin and Soft Tissue Infections in Marine Officer Candidates

CAndesartan vs LIsinopril Effects on the BRain

Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise

Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Effect of Minimally Processed Animal Protein on Biomarkers for Cognitive Decline

Safety of and Immune Response to an HIV Vaccine (SF-2 gp120) With or Without MTP-PE/MF59 Adjuvant

Exercise and Nutritional Intervention for Deconditioned Older Adults

Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell Carcinoma

A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma

Platelet Modulation: A Study of Angiogenic and Coagulation Proteins in Patients With Cancer

rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency

Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature

Phase III Study Comparing Efficacy and Safety of AFOLIA vs Gonal-f® RFF in Women (35 to 42) Undergoing IVF

Evaluating Simvastatin's Potential Role in Therapy

Breast Cancer Patients: A Breast Cancer Rehabilitation and Exercise Laboratory

NET-PD LS-1 Creatine in Parkinson's Disease

A Randomized Controlled Trial to Test the Effects Oxytocin and Vibration Have on Heat Pain Threshold After UV-B Burn

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V